Slide 1: Results Presentation for the Half Year Ended 31 December 2021
For personal use only For immediate release 16 February 2022 RESULTS PRESENTATION FOR THE HALF YEAR ENDED 31 DECEMBER 2021 Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the slides for the presentation on the half year results that will be given by the Chief Executive Officer
Slide 2: CSL Limited 2022 Half Year Results
For personal use only CSL Limited 2022 Half Year Results 16 February, 2022 Paul Perreault Joy Linton CEO and Managing Director CFO
Slide 3: Important Notice and Disclaimer
For personal use only IMPORTANT NOTICE AND DISCLAIMER This presentation contains summary information about CSL Limited (ACN 004 089 936) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form only and does no
Slide 4: CEO Overview
For personal use only CEO Overview Paul Perreault CEO & Managing Director
Slide 5: 1H22 Performance
1H22 Performance1 Revenue up 4% with net profit after tax down 5% For personal use only CSL Behring Seqirus CSL has performed in line with expectations • IDELVION® +17% • Seasonal influenza vaccines +20% As expected Ig & Albumin sales have been limited by COVID constrained • KCENTRA® +15% • Record v
Slide 6: CSL Behring: Revenue steady
CSL Behring Revenue steady For personal use only Revenue By Region1 Sales Change1 Therapy $m % Immunoglobulins 1,977 (9%) (23%) - IVIG 1,255 (11%) ROW - SCIG 722 (4%) 5% Albumin 571 1% 42% Asia Pac Haemophilia 587 5% 23% - Recombinants 372 12% US$4.4B North America - Plasma 215 (6%) 48% (4%) Special
Slide 7: Immunoglobulins
Immunoglobulins Sales down 9%1 For personal use only • Supply tightness has temporarily impacted growth • HIZENTRA® – Clear market leader in SCIG with ~60% market share – Continued steady uptake for CIDP in US: − ~three-quarters of targeted physicians have now utilised Hizentra to treat CIDP − Neuro
Slide 8: Albumin
Albumin Sales up 1%1 For personal use only China Other markets • Maintaining market • EU declined as local leadership with brand manufacturers increasingly differentiation and effective compete for volume HCP engagement • Decline in US as supply • Domestic and offshore constraints stem from plasma p
Slide 9: Haemophilia
Haemophilia Sales up 5%1 For personal use only Recombinant Coags PD Coags • IDELVION® +17%: • HUMATE® / HAEMATE® +2%: − Market leader in Haem B − Russia tender win − Compelling clinical profile • Decline in demand for drives patient demand & BERIATE® due to competitive market share pressure and swit
Slide 10: Specialty Products
Specialty Products Sales up 2%1 For personal use only HAE Hospital Products 1H22 Sales $914m HAEGARDA® +7% • KCENTRA® +15% Other • Successful launches in − Return to pre-pandemic Zemaira multiple EU countries, Canada demand levels Wound Healing & Australia • RIASTAP® / Haegarda • 80% of US patients
Slide 11: Plasma Collections: Volume Up 18%
Plasma Collections Volume Up 18% For personal use only Driving Growth Contemporary topics • Competitive donor fees • Omicron variant disruption to • Improved social mobility operations within COVID environment • Competitive US employment • Enhanced operating and environment marketing initiatives bri
Slide 12: Plasma Collections: Improving
Plasma Collections Improving For personal use only Donors Per Week • Annual tax season • Pandemic and lockdowns begin Holiday Season • Vaccine momentum • Further initiatives • Stimulus burn-off Initiatives US fiscal launched stimulus JAN FEB MAR APR MAY JUN JULY AUG SEP OCT NOV DEC Not to scale 2019
Slide 13: Seqirus: Revenue up 17%
Seqirus Revenue up 17%1 For personal use only Sales Change1 Revenue By Region1 Therapy $m % Egg Based 184 (28%) Seasonal Cell Culture 490 11% Influenza 11% vaccines Asia Adjuvanted Egg 838 48% +20% Pac Other / In-licence 80 (10%) Total Product Sales 1,592 18% EU / UK US$1.7B 63% 29% North 6% Pandemi
Slide 14: Seqirus Operating Highlights and Looking Forward
Seqirus For personal use only Operating Highlights Looking Forward • Record volume of ~110 million • Next generation self- doses distributed NH 21/22 amplifying mRNA: • EU: ‒ Phase 1 expected to ‒ Strong growth in differentiated commence cal. 2022 products ‒ Construction commenced on ‒ FLUAD® QIV1 l
Slide 15: R&D Highlights, Partnerships & Alliances
R&D Highlights Partnerships & Alliances For personal use only • CSL, WEHI, & University of Melbourne secured State Immunology Respiratory Government funding to create biotech start-up incubator in CSL’s new global headquarters, • Garadacimab (Anti-FXIIa) HAE • Garadacimab (Anti-FXIIa) IPF Phase II u
Slide 16: Agreement to Acquire Vifor Pharma Ltd
Agreement to Acquire Vifor Pharma Ltd For personal use only • Institutional placement for A$6.3 billion completed • Share Purchase Plan for A$750 million completed On 14 December 2021, • Debt - $6 billion bridge in place to be replaced by long term CSL announced a tender offer to acquire 100% of fun
Slide 17: Vifor Pharma: Compelling Strategic Rationale
Vifor For personal use only Pharma Strengthens CSL’s Materially Enhances Value Driven Scale and Free Cash Strategy Flow Compelling Strategic Rationale Builds a Significant Compelling Renal Franchise Financial Profile Extends the Reach of CSL’s High Value Pipeline 16
Slide 18: CSL's Rich Pipeline Aligns With Vifor's Renal Framework
CSL’s Rich Pipeline Aligns With Vifor’s Renal Framework For personal use only CKD Complications AKI (Ischemia – Reperfusion) Dialysis 1 INS-3001 Vadadustat Multiple Potential SNF-472 2 assets (Preclinical & Clinical) 3 Vadadustat4 5 3 1 CSL964 CSL964 Sparsentan6 GvHD treatment GvHD prevention (Phase
Slide 19: Financials
For personal use only Financials Joy Linton CFO
Slide 20: Financial Highlights: Net Profit After Tax
Financial Highlights Net profit after tax For personal use only -3% reported $1,810m $1,760m FX$38m $1,722m -5% @CC1 @CC1 • CSL has performed in line with expectations • Increased collections costs • Higher fixed cost absorption on lower plasma volumes • Includes $17m Vifor 1H21 1H22 transaction cos
Slide 21: Financial Highlights: CSL Group
Financial Highlights CSL Group For personal use only 1H21 1H22 1H22 Change 1 Reported Reported at CC % Total Revenue 5,739 6,041 5,993 4%1 Gross Profit 3,472 3,449 3,417 (2%)1 GP margin 60.5% 57.1% 57.0% EBIT 2,358 2,215 2,165 (8%)1 EBIT margin 41.1% 36.7% 36.1% NPAT 1,810 1,760 1,722 (5%)1 Cashflow
Slide 22: Financial Highlights: Segments
Financial Highlights Segments For personal use only CSL Behring Seqirus 1H21 1H22 Change 1H21 1H22 Change US$ Millions Reported Reported % at CC 1 US$ Millions Reported Reported % at CC 1 Sales 4,256 4,216 (2%) Sales 1,340 1,592 18% Other Other 59 140 139% 85 93 6% Revenue Revenue Total Total 4,315
Slide 23: Financial Highlights: R&D, Expenses and Tax
Financial Highlights R&D • Trials resuming post COVID pause Reported Expenses For personal use only • FY22 est. 10-11% of revenue Sales and Marketing 1 1H22 Change @ CC • Modest uplift in advance of $m $m % commercial launches Research & General Admin 486 57 13% Development • Higher I&T/SaaS Sales &
Slide 24: Our Sustainability Strategy
Our Sustainability Strategy For personal use only • Sustainability Strategy approved by the Board in 2021 • Executive Sustainability Committee representing all areas of the business CSL is committed to a healthier world. Our • Focused on 3 key strategic pillars – Environment, Social and vision is a
Slide 25: Outlook
Outlook FY22 result heavily skewed to 1H For personal use only CSL Behring • Improving plasma collections expected to underpin stronger Ig and albumin sales Seqirus • >80% of sales in 1H, with expenses falling more evenly over the year giving rise to a loss in 2H, consistent with seasonality CSL Gro
Slide 26: CSL Contacts
For personal use only CSL Contacts Mark Dehring VP Investor Relations +61 3 9389 3407 mark.dehring@csl.com.au Bernard Ronchi Investor Relations +61 3 9389 3470 bernard.ronchi@csl.com.au Stephen McKeon Investor Relations +61 3 9389 6798 stephen.mckeon@csl.com.au
Slide 27: Notes
Notes For personal use only (#) Constant currency removes the impact of Summary NPAT exchange rate movements to facilitate Reported net profit after tax $1,760.3m Translation currency effect (a) $ (9.0m) comparability of operational performance for the Transaction currency effect (b) $ (21.7m) Group